NYSE:CVD Covance (CVD) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free CVD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Covance alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Covance Stock (NYSE:CVD)Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him CVD Stock News HeadlinesFebruary 23, 2024 | msn.comNew study shows glycan sugar coating of IgG immunoglobulin can predict cardiovascular healthJanuary 26, 2024 | msn.comClinical study supports the long-lasting impacts of typhoid conjugate vaccineApril 25, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…October 8, 2023 | msn.com“Unblocked” movement to tackle burden of cardiovascular diseasesOctober 6, 2023 | reuters.comAntidumping separate rate process and pitfalls importers should considerSeptember 24, 2023 | investing.comCVD Historical DataAugust 26, 2023 | msn.comFeeling safe from crime ‘reduces heart attack risk’July 27, 2023 | finance.yahoo.comCVV - CVD Equipment CorporationApril 25, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 22, 2023 | benzinga.comHolter ECG Market is Expected to Reach $558 million | MarketsandMarkets.May 8, 2023 | technews.tmcnet.comUCARDIA ANNOUNCES ACQUISITION OF PHAS3; LAUNCHES CARDIOLOGIST PRACTICE REMOTE PATIENT MONITORING OFFERINGJuly 21, 2022 | marketwatch.comAnalgesics Market 2022 Size, Demand, Outlook, Trends, Revenue, Future Growth Opportunities till 2030May 10, 2022 | finance.yahoo.comPeople Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular CareMay 4, 2022 | thestreet.comCramer's 'Mad Money' Recap: Stake Out AeroVironmentMarch 14, 2022 | msn.comPeople with serious mental illness more likely to have heart disease – studyMarch 13, 2022 | msn.comPeople with serious mental illness more likely to suffer from heart disease – studyJanuary 31, 2022 | ca.finance.yahoo.com1 Top Healthcare Stock to Buy Low TodayJanuary 21, 2022 | thestreet.comCovance Stock Hits New 52-Week High (CVD)October 26, 2021 | finance.yahoo.comNovartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)September 28, 2021 | msn.comWorld Heart Day 2021: Know all about the date, history, significance and themeSee More Headlines Receive CVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Covance and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/04/2015Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CVD CUSIP22281610 CIK1023131 Webwww.covance.com Phone+1-609-4524440FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report CVD Stock Analysis - Frequently Asked Questions How were Covance's earnings last quarter? Covance Inc (NYSE:CVD) posted its earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share for the quarter, meeting the consensus estimate of $0.97. The healthcare company had revenue of $634 million for the quarter, compared to analysts' expectations of $631.30 million. What other stocks do shareholders of Covance own? Based on aggregate information from My MarketBeat watchlists, some companies that other Covance investors own include Allena Pharmaceuticals (ALNA), Laboratory Co. of America (LH), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB), Asterias Biotherapeutics (AST), Catalyst Biosciences (CBIO), Crestwood Equity Partners (CEQP), Cisco Systems (CSCO), Fate Therapeutics (FATE) and Flexion Therapeutics (FLXN). This page (NYSE:CVD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Covance Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
